Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks ag-biotech company Ceres said the U.S. Department of Agriculture told the company Feb. 17 that several corn traits Ceres developed do not need to be regulated under a USDA mandate. For years, Ceres developed genetically modified crops for use in biofuels. Last June, the company switched its focus to developing genetically modified crops Read More →